An anti–PD-1 monoclonal antibody formerly known as BMS-936558 (PMID 23714523). Approximate rate of pneumonitis is 3%, with 1% being severe (Grade 3/4). Incidence of pneumonitis is higher in those patients on concomitant nivolumab plus ipilimumab or other ICPI combo therapy (PMID 25891304)

Last update : 25/10/2018
I - Interstitial/parenchymal lung disease
II - Pulmonary edema - Acute lung injury - ARDS
III - Pulmonary/alveolar hemorrhage
IV - Airway involvement
V - Pleural and/or pericardial involvement
IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
X - Systemic conditions, syndromes and reactions
XI - Miscellaneous
XII - Cardiovascular involvement / toxicity
XV - Pathology
XVI - Imaging
XVII - Infections & related conditions